Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Radiopharmaceuticals for brain imaging

G B Saha1, W J MacIntyre, R T Go

  • 1Department of Nuclear Medicine, Cleveland Clinic Foundation, OH 44195-5074.

Seminars in Nuclear Medicine
|October 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A study on perception of facial expressions of emotions in depression.

Indian journal of psychiatry·2011
Same author

Cerebral perfusion and vascular reserve in fibromuscular dysplasia of the internal carotid artery.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2007
Same author

On FDG PET metabolic imaging to assess myocardial viability.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2000
Same author

Scintigraphic detection of post-pneumonectomy bronchopleural fistulae.

European journal of nuclear medicine·1999
Same author

Comparison of double-phase 99mTc-sestamibi with 123I-99mTc-sestamibi subtraction SPECT in hyperparathyroidism.

AJR. American journal of roentgenology·1997
Same author

Incremental value of rubidium-82 positron emission tomography for prognostic assessment of known or suspected coronary artery disease.

The American journal of cardiology·1997
Same journal

Letter from the Editors.

Seminars in nuclear medicine·2026
Same journal

Expanding Horizons: The Role of Kaleidoscope and Relevant Images in Seminars in Nuclear Medicine.

Seminars in nuclear medicine·2026
Same journal

The diagnostic performance and clinical value of [18F]FDG PET/CT in pleural mesothelioma - A systematic review and meta-analysis.

Seminars in nuclear medicine·2026
Same journal

Feasibility of treating neuroendocrine prostate cancer with anti-SSTR radioligands: A systematic review of imaging and treatment studies.

Seminars in nuclear medicine·2026
Same journal

<sup>18</sup>F-FDG -PET/CT in cardiac sarcoidosis: Diagnosis, therapy monitoring, and future directions.

Seminars in nuclear medicine·2026
Same journal

Maximizing diagnostic yield: A systematic review and deep dive into PSMA PET scan protocol variations for prostate cancer.

Seminars in nuclear medicine·2026
See all related articles

This study reviews radiopharmaceuticals for brain imaging using single photon emission computed tomography (SPECT) and positron emission tomography (PET). These agents aid in diagnosing brain tumors, cerebrovascular diseases, and neurological disorders.

Area of Science:

  • Nuclear medicine
  • Radiopharmaceutical chemistry
  • Neuroimaging

Background:

  • Single photon emission computed tomography (SPECT) and positron emission tomography (PET) utilize radiopharmaceuticals for brain imaging.
  • Radiopharmaceuticals are categorized by blood-brain barrier permeability, perfusion, metabolism, receptor binding, and antigen-antibody interactions.

Purpose of the Study:

  • To provide a comprehensive overview of radiopharmaceuticals used in SPECT and PET brain imaging.
  • To discuss the classification and applications of various brain imaging agents.

Main Methods:

  • Review of SPECT and PET radiopharmaceuticals based on their mechanism of action and targets.
  • Classification of agents by their ability to cross the blood-brain barrier, measure cerebral perfusion and metabolism, or bind to specific receptors.

Related Experiment Videos

Main Results:

  • SPECT agents like 99mTcO4- and [99mTc]HMPAO are used for tumor detection and assessing cerebrovascular diseases, respectively.
  • PET agents, particularly [18F]fluorodeoxyglucose (FDG), are crucial for detecting metabolic abnormalities, grading brain tumors, and diagnosing conditions like Alzheimer's disease and Parkinson's disease.
  • Various tracers are employed for measuring cerebral blood flow (CBF) and neurotransmitter activity.

Conclusions:

  • Radiopharmaceuticals play a vital role in diagnosing a wide spectrum of brain disorders using SPECT and PET.
  • The selection of appropriate radiopharmaceuticals is critical for accurate diagnosis and disease management in neuroimaging.